DrugPatentWatch Database Preview
Drugs in Development Information for Senicapoc
» See Plans and Pricing
What is the development status for investigational drug Senicapoc?
Senicapoc is an investigational drug.
There have been 4 clinical trials for Senicapoc.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2020.
The most common disease conditions in clinical trials are Anemia, Hemolytic, Congenital, Asthma, Exercise-Induced, and Asthma. The leading clinical trial sponsors are Icagen, Aarhus University Hospital, and Aalborg University Hospital.
There are thirteen US patents protecting this investigational drug and one hundred and four international patents.
Summary for Senicapoc
| US Patents | 13 |
| International Patents | 104 |
| US Patent Applications | 60 |
| WIPO Patent Applications | 39 |
| Japanese Patent Applications | 11 |
| Clinical Trial Progress | Phase 2 (2020-07-01) |
| Vendors | 65 |
Recent Clinical Trials for Senicapoc
| Title | Sponsor | Phase |
|---|---|---|
| Senicapoc and Dehydrated Stomatocytosis | Quest Diagnostics | Phase 3 |
| Senicapoc and Dehydrated Stomatocytosis | Boston Children’s Hospital | Phase 3 |
| Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency | Aalborg University Hospital | Phase 2 |
Clinical Trial Summary for Senicapoc
Top disease conditions for Senicapoc
Top clinical trial sponsors for Senicapoc
US Patents for Senicapoc
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Senicapoc | Start Trial | Methods for treating malaria using potassium channel inhibitors | THE CHILDREN'S MEDICAL CENTER CORPORATION (Boston, MA) | Start Trial |
| Senicapoc | Start Trial | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | First Wave Bio, Inc. (Ann Arbor, MI) | Start Trial |
| Senicapoc | Start Trial | Gardos channel antagonists | Icagen, Inc. (Durham, NC) | Start Trial |
| Senicapoc | Start Trial | Imines as ion channel modulators | Icagen, Inc. (Durham, NC) | Start Trial |
| Senicapoc | Start Trial | Method to treat sickle cell disease | University of Virginia Patent Foundation (Charlottesville, VA) | Start Trial |
| Senicapoc | Start Trial | Carbonylamino derivatives useful for the treatment of certain inflammatory disorders | Aniona Aps (Farum, DK) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Senicapoc
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Senicapoc | World Intellectual Property Organization (WIPO) | WO2016134353 | 2035-02-20 | Start Trial |
| Senicapoc | Australia | AU2016315852 | 2035-09-01 | Start Trial |
| Senicapoc | Canada | CA2997136 | 2035-09-01 | Start Trial |
| Senicapoc | Chile | CL2018000559 | 2035-09-01 | Start Trial |
| Senicapoc | China | CN109562137 | 2035-09-01 | Start Trial |
| Senicapoc | Colombia | CO2018003465 | 2035-09-01 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
